Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer

Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer

As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-induced neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer (DNPC) that is deficient for androgen receptor (AR) and neuroendocrine (NE) markers has increased. These prostate cancer subt...

Full description

Bibliographic Details
Main Authors: Daniel J. Turnham, Manisha S. Mullen, Nicholas P. Bullock, Kathryn L. Gilroy, Anna E. Richards, Radhika Patel, Marcos Quintela, Valerie S. Meniel, Gillian Seaton, Howard Kynaston, Richard W. E. Clarkson, Toby J. Phesse, Peter S. Nelson, Michael C. Haffner, John N. Staffurth, Helen B. Pearson
Format: Article
Language:English
Published: MDPI AG 2024-04-01
Series:Cells
Subjects:
patient-derived xenograft (PDX)
double-negative prostate cancer (DNPC)
castration-resistant prostate cancer (CRPC)
neuroendocrine (NE)
androgen receptor (AR)
Online Access:https://www.mdpi.com/2073-4409/13/8/673

Internet

https://www.mdpi.com/2073-4409/13/8/673

Similar Items